Cycloalkyl-containing carboxylic acids and uses thereof

A technology of alkyl and cycloalkane, applied in the field of cycloalkyl-containing carboxylic acid and its application, can solve problems such as edema and weight gain

Pending Publication Date: 2022-07-29
里米诺生物科学有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Finally, PPAR-γ agonists may cause weight gain and edema

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cycloalkyl-containing carboxylic acids and uses thereof
  • Cycloalkyl-containing carboxylic acids and uses thereof
  • Cycloalkyl-containing carboxylic acids and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0286] The preparation of solvates is generally known. Thus, for example, M. Caira et al., J. Pharmaceutical Sci., 93(3), 601-611 (2004) describe the preparation of solvates of antifungal fluconazole in ethyl acetate and water. Similar preparations of solvates, hemisolvates, hydrates, etc. are by E.C. van Tonder et al., AAPS Pharm SciTech., 5(1), paper 12 (2004); and A.L. Bingham et al., Chem. Commun., 603– 604 (2001) description. A typical non-limiting procedure involves dissolving a compound disclosed herein in the desired amount of the desired solvent (organic or water or a mixture thereof) at a temperature above ambient, and cooling the solution at a rate sufficient to form crystals, The crystals are then isolated by standard methods. Analytical techniques such as infrared spectroscopy show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).

[0287] pharmaceutical composition

[0288] In another aspect, the present disclosure provides a...

Embodiment 1

[0339] Example 1 : Synthesis of compounds

[0340] All HPLC chromatograms and mass spectra were recorded on an HP 1100 LC-MS Agilent instrument using an analytical C18 column (250 x 4.6 mm, 5 microns) with a gradient of 15-99% acetonitrile-water with 0.01% trifluoro over 5 min Acetic acid was used as eluent and the flow rate was 2 mL / min.

[0341] General Scheme for the Preparation of 2-Cyclopropyl Acetate Compounds

[0342]

[0343] R=F, Cl, Br or Me

[0344] Compound I: Synthesis of sodium salt of 2-(2,2-difluoro-3-hexylcyclopropyl)acetic acid

[0345]

[0346] step 1 : 3-Decenoic acid (10 g, 58.7 mmol) was dissolved in methanol (100 mL) at room temperature. Concentrated sulfuric acid (0.5 mL) was added and the reaction was stirred for 16 h. Saturated sodium bicarbonate solution (100 mL) was added, and the mixture was extracted three times with ethyl acetate. The organic layers were combined, washed with brine and dried over anhydrous sodium sulfate. The ...

Embodiment 2

[0643] Example 2 : Effects of representative compounds disclosed herein on the induction of hemoglobin production in vitro

[0644] The effect of representative compounds disclosed herein on the induction of hemoglobin production in human myeloid chronic myeloid leukemia cells (K562) was assessed using a 2,7-diaminofluorene (DAF) assay by pseudo-passage of free hemoglobin. Oxidase activity to measure DAF oxidation. K562 cells were incubated with various compounds (compounds I, II and III) at the stated concentrations for 5 days. On day 5, cells were centrifuged and washed in PBS. make 2x10 6 Cells were lysed in 140 μl NP-40 (0.01%, 5 min on ice). 2 mg of DAF (2,7-diaminofluorene, 97%, Aldrich, catalog #D17106-1G) was resuspended in 200 μl glacial acetic acid 90% and a working solution was prepared as follows: 100 μl DAF + 100 μl H 2 O 2 30% + 10ml Tris-HCl 0.1M / 6M Urea pH 7, Vortex. 50 μl of cell lysate was transferred to wells and 150 μl of DAF working solution was ad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

Disclosed are compounds of Formula (I) or salts thereof, as well as compositions comprising such compounds or salts thereof. Also disclosed is the use of such compounds, salts thereof, or compositions comprising such compounds, salts thereof for the treatment of anemia or leukopenia, fibrosis, cancer, hypertension, and / or metabolic disorders in a subject.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] Not applicable technical field [0003] The present disclosure relates to compounds, compositions, methods, and uses, such as for the prevention or treatment of multiple diseases caused by anemia, neutropenia, leukopenia, inflammation, hypertension, cancer, and / or fibrosis in a subject diseases and ailments. Background technique [0004] Hematopoiesis refers to the formation, development and differentiation of all types of blood cells. All cellular blood components are derived from hematopoietic stem cells, including white and red blood cells. White blood cells or white blood cells (WBCs) are cells of the immune system that defend the body against infectious diseases and foreign substances. Red blood cells are anucleated, biconcave, disc-shaped cells that contain hemoglobin, and these cells are necessary for oxygen transport. A decrease in the number of white blood cells is called leukopenia, and anemia refers to a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): A61P3/04A61P3/10A61P7/06A61P9/12A61P35/00C07C53/134C07C57/26C07D303/12
CPCC07C53/134C07C57/26C07D303/12A61P35/00A61P3/04A61P3/10A61P7/06A61P9/12C07C2601/02C07C2601/04C07C2601/14C07C2602/44C07C61/04C07C61/16C07B2200/05C07C53/23A61P19/04A61P13/12C07C53/132C07C53/136C07C55/28C07C57/03C07C59/11C07C59/205C07C61/08C07D211/34C07D241/04C07D303/38
InventorL·加尼翁F·莱布隆德L·格尔茨B·扎卡赖尔C·道尔J·马特尔J-S·杜斯培J-E·拉科斯特J-F·锡伯杜
Owner里米诺生物科学有限公司